Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | HPRT1 | P00492 | 3/20 | 0.52 |
| ▸ | PNP | P00491 | 4/20 | 0.51 |
| ▸ | AHCY | P23526 | 2/20 | 0.48 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.48 |
| ▸ | TK1 | P04183 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | EDNRA | P25101 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | HBB | P68871 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL600701 | 1.00 | ADORA3 (0.52) | ADORA3HPRT1PNPAHCYSTING1 | |
| SCHEMBL10171928 | 1.00 | ADORA3 (0.52) | ADORA3HPRT1PNPAHCYSTING1 | |
| SCHEMBL10647267 | 0.92 | ADORA3 (0.54) | ADORA3HPRT1PNPAHCYSTING1 | |
| SCHEMBL10364286 | 0.92 | ADORA3 (0.54) | ADORA3HPRT1PNPAHCYSTING1 | |
| SCHEMBL10364278 | 0.92 | ADORA3 (0.54) | ADORA3HPRT1PNPAHCYSTING1 | |
| SCHEMBL10364294 | 0.92 | ADORA3 (0.54) | ADORA3HPRT1PNPAHCYSTING1 | |
| SCHEMBL10364276 | 0.92 | ADORA3 (0.54) | ADORA3HPRT1PNPAHCYSTING1 | |
| SCHEMBL9308999 | 0.90 | PNP (0.59) | ADORA3HPRT1PNPAHCYTK1 | |
| SCHEMBL9309006 | 0.90 | PNP (0.59) | ADORA3HPRT1PNPAHCYTK1 | |
| SCHEMBL9309114 | 0.90 | PNP (0.59) | ADORA3HPRT1PNPAHCYTK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114994-B2 | 2′ and 3′-substituted cyclobutyl nucleoside analogs for the treatment viral infections and abnormal cellular proliferation | EMORY UNIVERSITY (US) | 2012-02-14 | — | — | US | disclosed |
| US-20090149416-A1 | 2' and 3'-Substituted Cyclobutyl Nucleoside Analogs for the Treatment Viral Infections and Abnormal Cellular Proliferation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-06-11 | — | — | US | disclosed |
| US-7495006-B2 | 2′ and 3′-substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation | EMORY UNIVERSITY (US) | 2009-02-24 | — | — | US | disclosed |
| US-20060223835-A1 | 2' and 3'- substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation | EMORY UNIVERSITY | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149416-A1 | 2' and 3'-Substituted Cyclobutyl Nucleoside Analogs for the Treatment Viral Infections and Abnormal Cellular Proliferation | HAVCR2, PNP, PCNA | ADORA3 790/4885HPRT1 4/4885PNP 2/4885 |
| US-20060223835-A1 | 2' and 3'- substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation | HAVCR2, PNP, DCTD | ADORA3 780/4885HPRT1 5/4885PNP 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.